Product Reports Resources Pricing Login Book a demo

METiS Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2017

AI-driven platform for drug discovery and delivery

Valuation $1–2.5B
Headcount <100
Unlock exact values This page shows ranges. Dealroom has the exact numbers for METiS Therapeutics and the history behind them.
Power Law Unicorn$1–10B valuation tier

Talent graph

METiS Therapeutics's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

17 investors on METiS Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 6 investors entered at this stage
Sequoia
Luminous Ventures
Source Code Capital
XtalPi
Frees Fund
Lightspeed Venture Partners
Series A 5 investors entered at this stage
China Life Private Equity Investment
HSG
China Life Insurance
5Y Capital
Picc Group
Series B+ 6 investors entered at this stage
PICC Capital
CMB International Capital
CICC
Monolith Management
Massachusetts Institute of Technology
China Taiping Insurance

Ownership

Who owns METiS Therapeutics

Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.

27.5% Founders

Some investors are hidden on this public profile. See the full cap table on Dealroom →

Global footprint

Where METiS Therapeutics has talent and traffic

Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown
Web traffic by country
2.8K monthly visits
across markets
🇺🇸 United States100%
Top 1 markets shown

Patent intelligence

$2M patent portfolio · 9 active families

Estimated portfolio value
$2M
0.14% of valuation · 236.4× smaller than top peer Genmab ($488M)
9 active patent families
Where METiS Therapeutics innovates Control systemData miningData scienceEyepieceNatural environment

Where METiS Therapeutics concentrates vs peers

Each axis is a top-10 topic across METiS Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about METiS Therapeutics

An AI-synthesized read of the highest-engagement posts about METiS Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See METiS Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles